X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (491) 491
animals (369) 369
male (359) 359
index medicus (337) 337
phenylbutyrates - pharmacology (304) 304
female (223) 223
mice (178) 178
phenylbutyrates - therapeutic use (160) 160
phenylbutyrates - administration & dosage (154) 154
adult (141) 141
pharmacology & pharmacy (127) 127
rats (125) 125
middle aged (108) 108
phenylbutyrate (107) 107
oncology (105) 105
sodium phenylbutyrate (101) 101
apoptosis (98) 98
histone deacetylase inhibitors (95) 95
aged (85) 85
biochemistry & molecular biology (84) 84
dose-response relationship, drug (79) 79
administration, oral (67) 67
expression (67) 67
er stress (64) 64
article (62) 62
endoplasmic reticulum stress - drug effects (62) 62
phenylbutyrates (61) 61
cancer (58) 58
disease models, animal (57) 57
mice, inbred c57bl (57) 57
time factors (57) 57
antineoplastic agents - pharmacology (56) 56
medicine, research & experimental (56) 56
research (56) 56
cell biology (55) 55
analysis (54) 54
isoindoles (54) 54
adolescent (52) 52
phenylbutyrates - adverse effects (52) 52
phenylbutyrates - pharmacokinetics (51) 51
phenylbutyric acid (51) 51
cell line, tumor (50) 50
cells, cultured (50) 50
neurosciences (50) 50
apoptosis - drug effects (49) 49
endoplasmic-reticulum stress (48) 48
proteins (48) 48
care and treatment (47) 47
hematology (46) 46
treatment outcome (45) 45
health aspects (43) 43
therapy (43) 43
unfolded protein response (43) 43
endoplasmic reticulum stress (42) 42
phenylacetate (42) 42
physiological aspects (42) 42
cells (41) 41
child (41) 41
endoplasmic reticulum (39) 39
antineoplastic agents - therapeutic use (38) 38
mutation (38) 38
stress (38) 38
clinical trials as topic (37) 37
gene expression (37) 37
inhibition (37) 37
acetylation (36) 36
endocrinology & metabolism (36) 36
metabolism (36) 36
genetics & heredity (35) 35
histones - metabolism (35) 35
rats, sprague-dawley (35) 35
cell line (34) 34
disease (34) 34
mouse model (34) 34
neoplasms - drug therapy (34) 34
oral sodium phenylbutyrate (34) 34
phenylbutyrates - chemistry (34) 34
rodents (34) 34
activation (33) 33
clinical neurology (33) 33
histone deacetylase (33) 33
inflammation (33) 33
liver (33) 33
phenylbutyrates - metabolism (33) 33
differentiation (32) 32
histone deacetylase inhibitors - pharmacology (32) 32
gastroenterology & hepatology (31) 31
histone deacetylase inhibitor (31) 31
medicine & public health (31) 31
ammonia (30) 30
enzyme inhibitors - pharmacology (30) 30
oxidative stress (30) 30
4-phenylbutyrate (29) 29
research article (29) 29
biphenyl compounds (28) 28
child, preschool (28) 28
gene-expression (28) 28
mice, transgenic (28) 28
urea cycle disorders (28) 28
double-blind method (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (735) 735
Italian (9) 9
Chinese (8) 8
French (8) 8
German (4) 4
Russian (4) 4
Japanese (3) 3
Polish (3) 3
Czech (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neurochemistry, ISSN 0022-3042, 06/2007, Volume 101, Issue 6, pp. 1491 - 1504
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 09/2008, Volume 28, Issue 38, pp. 9342 - 9348
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2009, Volume 15, Issue 12, pp. 3958 - 3969
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 01/2017, Volume 60, Issue 2, pp. 710 - 721
Journal Article
Journal Article
Journal Article
Anticancer Research, ISSN 0250-7005, 07/2012, Volume 32, Issue 7, pp. 2407 - 2413
Background: The malignant brain tumour glioblastoma is a devastating disease that remains a therapeutic challenge. Materials and Methods: Effects of... 
U251 MG | Proteasome inhibitor | Glioblastoma | Stem cells | HDAC inhibitor | R11 stem cells | GL15 cells | TB101 | stem cells | HISTONE DEACETYLASE INHIBITOR | GAP-JUNCTION COMMUNICATION | SUBEROYLANILIDE HYDROXAMIC ACID | PROTEASOME INHIBITION | INDUCED APOPTOSIS | RECURRENT GLIOBLASTOMA | ORAL SODIUM PHENYLBUTYRATE | DOSE-ESCALATION | PHASE-II TRIAL | proteasome inhibitor | ONCOLOGY | CANCER-TREATMENT | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Humans | Pyrazines - administration & dosage | Brain Neoplasms - pathology | Histone Deacetylase Inhibitors - administration & dosage | Valproic Acid - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Phenylbutyrates - administration & dosage | Hydroxamic Acids - administration & dosage | Neoplastic Stem Cells - pathology | Phenylbutyrates - pharmacology | Boronic Acids - administration & dosage | Hydroxamic Acids - pharmacology | Bortezomib | Neural Stem Cells - drug effects | Brain Neoplasms - drug therapy | Neural Stem Cells - pathology | Drug Synergism | Valproic Acid - administration & dosage | Glioblastoma - pathology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Glioblastoma - drug therapy | Pyrazines - pharmacology | Boronic Acids - pharmacology | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Cancer och onkologi
Journal Article
Frontiers in Bioscience - Elite, ISSN 1945-0494, 01/2011, Volume 3, Issue 4, pp. 1375 - 1384
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 10, pp. 16367 - 16386
Journal Article
Blood, ISSN 0006-4971, 04/2007, Volume 109, Issue 7, pp. 2781 - 2790
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, pp. e0120064 - e0120064
Background Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. Antineoplaston A10 and AS2-1 reportedly... 
COLON-CANCER | SURVIVAL | HEPATOCELLULAR-CARCINOMA | PHENYLACETATE | RESECTION | MULTIDISCIPLINARY SCIENCES | GROWTH | CELLS-IN-VITRO | PHENYLBUTYRATE | DIFFERENTIATION | HISTONE DEACETYLASE INHIBITORS | Colorectal Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Piperidones - therapeutic use | Antimetabolites, Antineoplastic - administration & dosage | Hepatectomy | Fluorouracil - therapeutic use | Benzeneacetamides - therapeutic use | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Phenylacetates - therapeutic use | Glutamine - analogs & derivatives | Liver Neoplasms - secondary | Phenylacetates - administration & dosage | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Treatment Outcome | Benzeneacetamides - administration & dosage | Piperidones - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Glutamine - administration & dosage | Survival Analysis | Glutamine - therapeutic use | Aged | Drug Combinations | Infusions, Intra-Arterial | Ablation (Surgery) | Liver diseases | Peptides | Adjuvant treatment | Colorectal cancer | Metastasis | Cancer | Fluorouracil | Adenocarcinoma | Therapy | Renal function | 5-Fluorouracil | Toxicity | Liver | Colorectal carcinoma | Clinical trials | Amino acids | Cancer therapies | Metastases | Liver cancer | Infusion | Randomization | Salvage | Surgery | Bone marrow | Colon | Urine | Stomach | Departments | Organs | Phlebitis | Patients | Ablation | Survival | Medicine | Chemotherapy | Medical prognosis | Epigenetics | Prostate cancer | Tumors | Apoptosis | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 06/2006, Volume 66, Issue 12, pp. 6361 - 6369
Optimal reexpression of most genes silenced through promoter methylation requires the sequential application of DNA methyltransferase inhibitors followed by... 
ACUTE-LEUKEMIA | CYTIDINE DEAMINASE GENE | CPG ISLAND METHYLATION | ONCOLOGY | ARA-C SENSITIVITY | HYPOMETHYLATING AGENT | COLORECTAL-CANCER | RISK MYELODYSPLASTIC SYNDROME | LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE | ORAL SODIUM PHENYLBUTYRATE | ELDERLY-PATIENTS | Azacitidine - adverse effects | Humans | Leukemia, Myeloid - genetics | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Phenylbutyrates - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors | Feasibility Studies | Myelodysplastic Syndromes - enzymology | Dose-Response Relationship, Drug | Phenylbutyrates - pharmacokinetics | Phenylbutyrates - administration & dosage | Aged, 80 and over | Female | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Promoter Regions, Genetic | Acute Disease | Azacitidine - pharmacokinetics | Myelodysplastic Syndromes - metabolism | Histone Deacetylases - genetics | Leukemia, Myeloid - enzymology | Treatment Outcome | DNA (Cytosine-5-)-Methyltransferases - genetics | Leukemia, Myeloid - drug therapy | Acetylation - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Myeloid - metabolism | Aged | Histone Deacetylase Inhibitors | Myelodysplastic Syndromes - genetics | Histones - metabolism | DNA Methylation - drug effects
Journal Article